157 related articles for article (PubMed ID: 36921527)
1. Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1.
Lu G; Nie W; Xin M; Meng Y; Jiang J; Gu J; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2023 May; 251():115243. PubMed ID: 36921527
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lin C; Liu C; Hu P; Zou Z; Sun G
Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
[TBL] [Abstract][Full Text] [Related]
4. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
5. New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.
Syam YM; Anwar MM; Abd El-Karim SS; Elokely KM; Abdelwahed SH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956876
[TBL] [Abstract][Full Text] [Related]
6. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.
Yu L; Wang YD; Yan ZW; Zhang LY; Li S
Bioorg Chem; 2024 Jul; 148():107480. PubMed ID: 38772291
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.
Guo C; Wang L; Li X; Wang S; Yu X; Xu K; Zhao Y; Luo J; Li X; Jiang B; Shi D
J Med Chem; 2019 Mar; 62(6):3051-3067. PubMed ID: 30844273
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
10. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.
El-Ghobashy NM; El-Sayed SM; Shehata IA; El-Ashmawy MB
Sci Rep; 2022 Sep; 12(1):16246. PubMed ID: 36171229
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
13. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor.
Liu X; Wei X; Li X; Yu R; Jiang T; Zhao C
Bioorg Med Chem; 2022 Sep; 69():116892. PubMed ID: 35764034
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation.
Zheng L; Ren R; Sun X; Zou Y; Shi Y; Di B; Niu MM
J Med Chem; 2021 Nov; 64(21):15702-15715. PubMed ID: 34670362
[TBL] [Abstract][Full Text] [Related]
16. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
[No Abstract] [Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]